Introduction
The rising burden of being overweight and obesity on healthcare services, as well as on personal wellbeing, is well documented, with many obesity-related comorbidities, including type 2 diabetes (T2DM), hypertension, infertility, sleep apnoea, depression, arthritis and various cancers (1, 2) . The Scottish Intercollegiate Guidelines Network guidance on the management of obesity recognises a need to achieve and maintain ≥15 kg (≥10%) weight loss with severe and complex obesity (2) . This target is principally justified by the aims of achieving remissions of T2DM initially demonstrated in patients undergoing bariatric surgery (3) and as demonstrated in the Diabetes Remission Clinical Trial (DiRECT) randomised controlled trial (RCT) (4) . Greater weight loss is also needed to manage sleep apnoea and arthritis optimally, as well as to allow obese patients to benefit from surgical procedures; for example, in gynaecology, fertility services and joint replacement surgery (5) . Bariatric surgery is widely recommended in evidencebased guidelines for severe and complex obesity [usually body mass index (BMI) >40 kg m À2 or 35 kg m À2 with comorbidities]. However, fewer than 1% of those eligible actually access surgery in most countries (6) . As a lowercost alternative to surgery, RCTs using total diet replacement (TDR) low energy formula diets, which provide 100% of the recommended daily intakes for vitamins and minerals, have shown weight losses of 10-15 kg, maintained for at least 12 months, with striking clinical benefits among patients with T2DM, sleep apnoea and osteoarthritis (7) (8) (9) . TDRs provide >800 kcal day -1 to <1200 kcal day -1 (>33.47 MJ day -1 to <50.21 MJ day -1 ) and meet the nutritional specifications set out in the The Foods Intended for Use in Energy Restricted Diets for Weight Reduction Regulations 1997 implementing Commission Directive 96/8 (10) . The Counterweight Programme initially focused on establishing standard 5-10 kg weight loss methods for service provision within the UK National Health Service (NHS). However, the mean BMI of referrals was consistently 37 kg m À2 , with 25% above 40 kg m À2 (11) . Subsequently, with Scottish Government Health Department funding, Counterweight-Plus was developed and established to address the 'intervention gap' before referral to bariatric surgery, as well as to satisfy clinical weight loss targets for people with severe and medically complex obesity (2, 12) . The resulting structured, nonsurgical programme, which aimed at achieving and maintaining >15 kg weight loss for as many patients as possible, has been commissioned by a number of UK NHS and private health agencies. Data from all patients are collected centrally for analysis to inform Continuous Improvement. In the present study, we report the results from a complete prospective audit over the 4-year period after the introduction of Counterweight-Plus, and illustrate how outcomes can be improved using the principles of Continuous Improvement Methodology (CIM), as used from 2001 onward by Counterweight (11) .
Materials and methods
This service evaluation adheres to the SQUIRE reporting guidelines (13) .
Following the published feasibility study (12) and CIM review, Counterweight-Plus was made available to public and private healthcare agencies in 2013 through Counterweight Ltd. The service is managed by a small central team of registered healthcare professionals with specialist training in weight management, with access to consultant physician expertise.
Practitioner training/support
To be certified to deliver Counterweight-Plus, practitioners (mainly Registered Dietitians) complete 2 days of training from Counterweight specialists, as well as a detailed case study. Counterweight Ltd trainers provide further supervision and mentoring via e-mail, telephone, webinar and annual study days. Competency is reassessed annually from practitioner outcomes or completion of a further case study, with further training and mentoring as necessary.
Target patient population and referral
The service targets patients requiring weight loss of the magnitude of approximately >15 kg or >10% for those with a lower baseline weight. For NHS patients, in areas where funding or part-funding for Counterweight-Plus is available, the service is provided by dietetic departments with referral from clinical specialties where weight loss is core to the clinical outcome; for example, T2DM care, bariatric surgery, etc. Counterweight-Plus can also be accessed through private health practitioners. On referral, practitioners communicate with general practitioners (GPs) regarding medical management of the patient, particularly over the need to review medications for T2DM and hypertension. Standard protocols support this process.
Programme structure and implementation

Screening
Initial screening ensures that patients meet the entry criteria of age 18-75 years, BMI >30 kg m À2 or BMI >27 kg m À2 plus associated T2DM, as well as an appropriate stage of readiness to change based on the Readiness Ruler (2) , in conjunction with checking for exclusion criteria, including active mental illness, myocardial infarction or stroke within the previous 3 months, severe or unstable heart failure, porphyria, pregnant until >4 months post-partum, breastfeeding, substance abuse or eating disorder accompanied by purging.
The programme stages are detailed in Fig. 1 . Appointments are 60 min for the initial session of the TDR and food reintroduction (FR) stages; all other appointments were 20 min Counterweight-Plus utilises behaviour change strategies from the CALO-RE taxonomy to support long-term lifestyle modification, including barrier identification and problem-solving, goal setting-action planning and review of outcome goals prompts (14) . Medical and weight change expectations are also discussed. High-quality patient and practitioner resources are used throughout the programme. Sachets comply with specifications for TDR products (10) . Structured discussions supported by written resources around goal-setting, relapse management, planning and physical activity start during TDR.
Total diet replacement
Advice around potential side effects is discussed and provided in patient materials. Patients are advised to use laxatives, with constipation being a common problem as a result of the low fibre content of the sachets.
Food reintroduction
This phase consisted of six appointments, re-introducing food-based meals stepwise over 6-12 weeks to allow flexibility to accommodate individual needs and time courses for confident transfer onto normal meals. Increased physical activity is advised aiming for 30 min of moderate activity per day on at least 5 days per week. Once this is achieved, individuals are advised to aim for 45-60 min of moderate activity per day (monitoring with step-counters or activity trackers if possible) (15) . Further nutrition and physical activity information is provided, encompassing recognised behavioural strategies (14) . Orlistat is available as an option depending on local prescribing access.
Weight loss maintenance
Seven appointments aim to consolidate behavioural change strategies and restrict weight regain to under 2 kg at 12 months. A second year of weight loss maintennance (WLM) is also available for commissioning depending on local funding.
Relapse management
If there is weight regain above a predefined acceptable level of 2-4 kg, a 4-8 week 'Rescue Plan' of TDR and/or FR is offered, along with a structured weight regain review and associated materials.
Medical and practitioner support
Any medical queries from practitioners or GPs are submitted to an experienced consultant weight management physician, using a standard medical query form. Queries and suggestions from practitioners' specific to the programme are dealt with by specialist Counterweight Dietitians. These queries and responses are circulated to all practitioners as 'Frequently Asked Questions' and contribute to CIM.
Evaluation methods
Practitioners delivering Counterweight-Plus are given an EXCEL database (Microsoft Corp., Redmond, WA, USA) to collect standard anonymised data for each patient enrolled into the programme, including reasons for loss to followup, and are then asked to return the database annually for central analysis. Patients are asked to sign a 'promise agreement' at the first visit where they commit to the programme and related sessions and consent is sought for anonymised data being used for programme evaluation. For patients who had withdrawn from the intervention, data were collected at 12 months (within a pragmatic 'window' of 9-18 months), where available, from measurements recorded at routine medical attendances.
Statistical analysis
For analysis purposes, and as a result of the rolling nature of programme enrollment, predefined rules are applied for eligibility for analysis within time frames and programme stages, and criteria for loss to follow-up. Resulting data are then checked for errors. In addition to summary statistics and percentages, formal statistical tests included: t-tests to assess differences in weight change between groups; univariate and multivariate regressions, including sex, diabetes status, age and BMI, to estimate the effect of continuous variables on weight change; and chi-squared tests to determine the significance of the association between categorical variables. Bonferroni adjustment of P-values was performed to account for potential type 1 error in performing repeated t-tests. Twelve-month outcomes are presented for attenders and additional intention-to-treat (ITT) analyses used single imputation with 12-month weights from GP records available for patients withdrawn from the intervention, as well as last observation carried forward (LOCF) and baseline observation carried forward (BOCF) to allow comparisons with other published studies using similar methodologies.
Ethics
The protocol was previously reviewed for the by West of Scotland Research Ethics Service, which concluded that formal ethical approval was unnecessary because no new or untested treatment was being offered and there was no experimentation (12) . This clinical audit of routine care therefore required no formal ethical approval.
Results
Between January 2013 and December 2016, 288 patients had enrolled in the Counterweight-Plus programme from nine UK Health Service areas (n = 222), one private weight-management service (n = 12) and eight individual private freelance Counterweight-Plus trained practitioners (n = 54). Mean (SD) baseline characteristics were: age 47.5 (12.7) years, weight 128.0 (32.0) kg and BMI 45.7 (10.1) kg m À2 , n = 76 (26.5%) were male and n = 99 (34.5%) had diabetes (97% T2DM) ( Table 1) . At the time of analysis 277, 246 and 217 patients were potentially eligible for 3-, 6-and 12-month weight change analysis, respectively, as a result of the rolling entry into audit. The numbers of eligible patients who attended at these time points was n = 247 (89%), n = 174 (71%) and n = 121 (56%). In those attending at 12 months, mean number of appointments was 16 (4.4). Data were obtained from GP records for 19 patients who had ceased to attend, showing a mean (SD) loss of 6.0 (8.5) kg at 12 months.
Mean (SD) weight losses (kg) in attenders were 12.7 (8.0) kg, 15.8 (9.9) kg and 14.2 (11.6) kg at 3, 6 and 12 months, respectively. Mean loss at 12 months by ITT analyses was single imputation -10.5 (9.5) kg, LOCF -10.9 (11.6) kg and BOCF -7.9 (11.1) kg. A target weight loss of 15 kg at 12 months was achieved by 22%, and >10% loss was achieved by 28%, with respect to all patients entering the programme. Among the 56% who continued engagement up to 12 months, 40% maintained a weight loss of >15 kg, with a mean loss of 14.2 kg. In addition to the target of 15 kg, a clinically beneficial weight loss of >5 kg was achieved at 3, 6 and 12 months by n = 216 (78%), n = 161 (65.4%) and n = 96 (44.2%), respectively, on an ITT basis. Summary weight changes are given in Table 2 , showing the follow-up and mean loss for attenders, and by ITT (single imputation, BOCF and LOCF) at each time point, as well as numbers (%) achieving the defined categories of weight change. Figure 2 illustrates the proportion of attenders in each weight-loss category and lost to followup for each data time point. Table 3 outlines through multivariate regressions that baseline BMI and sex had a significant impact on weight change at each time point: on average males, and those with higher BMI at baseline, lost more weight. The presence of diabetes and age had no significant impact.
Weight loss at 12 months was positively related to the weight change that had been achieved at 3 and 6 months. For every 1 kg greater weight loss at 3 and 6 months, weight loss at 12 months was greater by 0.9 kg (95% confidence interval = 0.72-1.11) and 1.1 kg (95% confidence interval = 0.98-1.18) respectively.
Later entry to the programme, over the 4-year observation period, was significantly related to better 12-month retention: 73.8% for those starting after the midpoint (March 2014 to December 2016) compared to 52.6% in those starting prior to the midpoint of recruitment (January 2013 to March 2014) (P < 0.01).
For relapse management, brief 'rescue plans' were given to 30 of the 217 patients eligible for 12-month follow-up (14%).
Longer support beyond 12 months has been offered by some practitioners, and follow-up data at 24 months were available for 46 (35%) of 131 who had started more than 2 years prior to the audit date. Their mean (SD) loss at 24 months was 13.5 (14.8) kg with 39% maintaining the target loss of >15 kg.
Discussion
No previous published evaluation has examined a TDR method outside of a specialist centre setting or clinical trial. Our audit and service evaluation has presented data on all 288 obese patients who entered a structured nonsurgical intensive weight-management programme. The patients enrolled had severe and complex obesity at baseline: mean BMI was 46 kg m À2 and 34% had T2DM.
This severity and complexity of obesity requires greater weight loss than conventional 'lifestyle only' programmes *The rolling nature of programme recruitment resulted in fewer people being eligible for the latter data capture time points. **Because 24 months follow-up is not routinely provided at this stage, only those followed up at 24 months are eligible. ***P < 0.01 for both one-sample t-test and Wilcoxon signed-rank test at all time points. Weight change at 3 months compared to baseline was analysed using a one-sample t-test, with a null hypothesis of H 0 : weight change at 3 months = 0. This is equivalent to a paired t-test comparing weight at 3 months versus baseline, testing the null hypothesis of H 0 : weight at 3 months = weight at baseline. This test was repeated for 6 and 12 months compared to baseline. Bonferroni adjustment had no effect on the significance of the P-values. can achieve; hence, there is a need for a nonsurgical intensive intervention because access to bariatric surgery is limited globally and also holds low appeal for large numbers (16) . The Counterweight-Plus programme achieved weight loss of 14.2 kg at 12 months in the attending population, reflecting considerably greater maintained weight loss than is reported with conventional diet and lifestyle interventions, with no worse adherence to this more intensive programme (11) . In this evaluation, baseline characteristics associated with greater 12-month weight loss included higher baseline BMI and being male. It is notable that the men achieved greater weight losses (mean 18.8 kg), even though 58% of men had diabetes, and the results were equally good for people with diabetes, in contrast to previous published work in weight management (17) . Evidence is accumulating that with a weight loss of the order of 15 kg, remission of T2DM may be possible for large numbers, bringing major personal, social and medical benefits, as well as avoiding the costs of medications prescribed to people with T2DM. Lim et al. (8) showed that remission of T2DM resulted from weight loss approximately 15 kg, using 8 weeks of TDR, with loss of the ectopic fat in liver and pancreas, and restoration of firstphase insulin release. The DiRECT RCT published 12-month outcomes showing T2DM remission rates of 86% with weight loss of ≥15 kg and 73% with weight loss of ≥10 kg using Counterweight-Plus (4) . Outcomes for Counterweight-Plus at 12 months in our service evaluation are reassuringly similar to many published high-quality RCTs of formula diet interventions (18) . There are no directly comparable routine-service evaluations; however, published outcomes are available from an Australian specialist tertiary hospital multidisciplinary weight management clinic, which used an initial full or partial very-low-energy diet [550 kcal day À1 (23.01 MJ day À1 ) very low energy diet] with monthly/bimonthly attendance, followed by stepped FR and WLM review every 1-3 months (19) . Despite the specialist multidisciplinary support, 12-month outcomes were better for Counterweight-Plus both in terms of attenders weight change: 12.7 kg versus 9.7 kg and loss to follow-up; 44% versus 58%.
The present data add to growing evidence that greater, more rapid, early weight-loss leads to better longer-term outcomes. Weight loss at 3 and 6 months was positively correlated with outcomes at 12 months. This counters the widespread assumption that rapid initial early weight-loss is quickly regained on reverting to a food-based diet (20) . The TDR approach was favourably received by patients. Programme retention was exceptionally high during TDR at 89%: motivation is high when weight loss is rapid (20) . The complete step away from usual food and drink allows the opportunity to re-educate and consolidate long-term plans for food choice and weight control, using a range of behaviour change strategies, delivered by a trained health professional.
Loss to follow-up is a common problem with weight management and other lifestyle interventions (21) . The use of formula diet in RCT studies have shown loss to follow up rates of 17-21% (4, 22) In one investigation, study participants were seen weekly and given ongoing free of charge formula product as part of the WLM intervention (22) , although this high level of retention may also reflect the population recruited being committed to the research being carried out. However, in other weight management RCTs where patients have volunteered to be part of a scientific study, often with incentives, 12-month loss to follow-up is commonly over 40% (23) , similar to that seen in the present service evaluation. In non-RCT interventions, a specialist UK service including psychology, dietetics and exercise therapists published an 80% loss to follow-up at 12 months (24) The results for the Counterweight-Plus service evaluation showed a reduced loss to follow-up, and also better weight-loss outcomes, for patients who started the programme after the 2-year midpoint date of the 4-year period for enrollment reported in the present study. This improvement may partly represent the success of the CIM integral to Counterweight-Plus, where practitioners report problems and ideas for programme refinements, and ongoing central review of the results identifies areas for further training or greater support. However, increased confidence and experience of practitioners would also contribute to the improved outcomes. Sensitivity analysis on imputed data showed a greater weight loss in attenders than in those who did not attend (LOCF: 10.9 kg; BOCF 7.9 kg); however, we do not have information on those failed to attend at the 12-month time point and therefore what their weight change would be. Although outcomes on attender cases may overestimate the effect of the programme, this conclusion could only be confirmed with actual weight change data for those not attending.
As with all weight management studies, there was some regain from the greatest mean weight loss of 15.8 kg at 6 months to 14.2 kg at 12 months. Rescue plans had been given to 30 of the 217 patients eligible for 12-month follow-up (14%). Weight loss at 12 months was no worse for those receiving rescue plans, and so this measure was having the intended effect. The data indicate no major rebound weight regain, with a mean regain of 1.6 kg (10% of total weight loss) between 6 and 12 months. Our limited 24-month data suggest that a significant proportion already maintain their weight loss in the longer term.
The main limitations of this service evaluation lie in access around wider data of interest such as details of changes in related clinical conditions (e.g. T2D), recorded information around side effects such as constipation and outcomes for patients who withdraw from the intervention. Improved resource would be needed to address this coupled with systems to automatically access associated patient outcomes and prescribing data such as information on the use of orlistat. Feedback from practitioners suggested a very low uptake of orlistat as an option; however, without specific details on this, the potential influence on weight change should not be discounted. A further limitation is that the focus is on 12-month outcomes; however, this again is largely driven by the available resource within routine NHS weight management. Finally, there may be recruitment bias and a control arm would add to the conclusions drawn.
In summary, Counterweight-Plus provides a practical option for patients who need to lose more weight than is achieved through conventional lifestyle interventions but for whom bariatric surgery is unavailable or unacceptable. Unlike many treatments, the results are equally good for people with diabetes. Outcomes compare favourably with the DiRECT RCT despite a more medically complex group and non-RCT delivery and support structure. Using CIM, the programme has been enhanced by providing greater flexibility, which has improved acceptability and, in turn, his has improved retention and weight loss. Further improvements to the programme include offering longer-term support for WLM with dynamic approaches for the prevention of weight regain, as well as the development of a digital option. Future research to improve longer term WLM is warranted, and more high-quality audits of real-life management in routine services should be published (25) .
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